City-based Aurobindo Pharma Limited has received approvals from the Medicines Control Council (MCC) to manufacture and market 9 products in South Africa.

<tr><td><p class='TableClas'></p><P class='TableClas'><DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>The products are estimated to be having a generic size of ZAR 165 million. The products include Auro - Lisinopril Co, Auro-Amlodipine, Auro - Finasteride, Zinoxime, Zolid, Yomax, Lazivir, Lisinozide and Profina. With these, Aurobindo has a total of 31 authorisations approved by the MCC, according to a company press release. </P></p><p class='TableClas'></p></table>


Aurobindo Pharma to make 9 products in South Africa

More From This Section

Posco land acquisition resumes amid protests

Diageo to buy half of Mallya's South Africa beer biz

Average money spent for new players dips

'IndiGo did not comply with AAC guidelines'

Explore News